Frank McCormick and his group at Onyx Pharmaceuticals were the first to propose taking advantage of this similarity in creating a virus that would selectively replicate in and destroy tumour cells carrying mutations of the p53 tumour suppressor gene (Bischoff et al, 1996). The gene discussed is TP53; the disease is neoplasm.